CELU Class A Celularity Inc. - Class A Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ 10-K/10-Q Oct 20, 2026
$0.75
· of 52w range
· above low
· to high
$0.5652w low
$2.5552w high
Market Cap (MRQ)
$22M
P/E
-0.3
EPS
$-3.59
Revenue
$27M
your badges
52W Range
$1–$3
Analyst Rating
BUY
Price Target
·
P/E
-0.3
ROE
·
Net Profit Margin
·
Your badge strip is empty — pin a metric anywhere on this page.
CELU Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$0.75
Market Cap (MRQ)
$22M
P/E
-0.3
EPS
$-3.59
Revenue
$27M
52W Range
$1–$3
CELU Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Stock splits
| Ex-date | Split | Type |
|---|---|---|
| Feb. 29, 2024 | 1-for-10 | Reverse |
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$27M2024-12-31 → 2025-12-31
EPS$-3.592024-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | CELU | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | -0.3 | · | · | · | |
| P/B (MRQ) | -0.6 | · | · | · | |
| Price / Tangible Book (MRQ) | -0.5 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | CELU | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 0.1 | · | 3.8 | Low liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | CELU | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | -51.0% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | CELU | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue / Employee | ≈$230.9K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-298.0%
Next Report
Nov 12, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| Dec. 31, 2025 | May 7, 2026 | $-0.85 | $-1.53 | 44.4% |
| Sept. 30, 2025 | $-0.88 | $-1.53 | 42.5% | |
| June 30, 2025 | $-1.02 | $-0.77 | -33.3% | |
| March 31, 2025 | $-0.84 | $-0.77 | -9.8% | |
| Sept. 30, 2023 | $-5.00 | $-0.31 | -1534.0% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Revenue | $27M | $54M | |
| Cost of Revenue | $20M | $15M | |
| R&D Expense | $15M | $17M | |
| SG&A Expense | $51M | $59M | |
| Operating Income | $-61M | $-38M | |
| Other Non-op | · | $2M | |
| Pretax Income | $-92M | $-58M | |
| Income Tax | $3.0K | · | |
| Net Income | $-92M | $-58M | |
| EPS (Basic) | $-3.59 | $-2.64 | |
| EPS (Diluted) | $-3.59 | $-2.64 | |
| Shares (Basic) | 25,598,586 | 21,890,518 | |
| Shares (Diluted) | 25,598,586 | 21,890,518 |
Balance Sheet
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Cash & Equivalents | $6M | $738.0K | |
| Receivables | $5M | · | |
| Inventory | $571.0K | $5M | |
| Prepaid Expense | $920.0K | $857.0K | |
| Current Assets | $12M | $21M | |
| PP&E (Net) | $56M | $62M | |
| PP&E (Gross) | $94M | $94M | |
| Accum. Depreciation | $39M | $33M | |
| Goodwill | $7M | $7M | |
| Intangibles | $8M | $9M | |
| Other Non-current Assets | $247.0K | $270.0K | |
| Total Assets | $107M | $133M | |
| Accounts Payable | $26M | $23M | |
| Accrued Liabilities | $33M | $20M | |
| Current Liabilities | $81M | $54M | |
| Capital Leases | $27M | $27M | |
| Deferred Tax | $12.0K | $9.0K | |
| Other Non-current Liabilities | $266.0K | $280.0K | |
| Total Liabilities | $145M | $124M | |
| Common Stock | $3.0K | $2.0K | |
| Paid-in Capital | $953M | $909M | |
| Retained Earnings | $-991M | $-900M | |
| AOCI | · | $-5.0K | |
| Stockholders' Equity | $-38M | $9M | |
| Liabilities + Equity | $107M | $133M | |
| Shares Outstanding | 28,837,787 | 22,546,671 |
Cash Flow
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| D&A | $7M | $8M | |
| Amort. of Intangibles | $1M | $2M | |
| Operating Cash Flow | $-13M | $-6M | |
| CapEx | · | $161.0K | |
| Investing Cash Flow | · | $514.0K | |
| Stock Issued | $1M | · | |
| Financing Cash Flow | $19M | $7M | |
| Net Change in Cash | $5M | $814.0K | |
| Taxes Paid | $52.0K | · |
Per Share
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| EPS (TTM) | $-3.59 | · |
Growth Rates
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Revenue YoY | -51.0% | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Revenue TTM | $27M | · | |
| Net Income TTM | $-92M | · | |
| P/E | -0.3 | · | |
| Earnings Yield | -323.4% | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Revenue | $5M | $4M | $4M | $11M | $18M | |
| Cost of Revenue | $2M | $1M | $7M | $4M | $7M | |
| R&D Expense | $2M | $3M | $3M | $4M | $4M | |
| SG&A Expense | $5M | $9M | $15M | $14M | $16M | |
| Operating Income | $-4M | $-10M | $-22M | $-10M | $-9M | |
| Interest Income | $11.0K | $62.0K | · | $76.0K | · | |
| Other Non-op | $-11.0K | $-609.0K | · | $-1M | $17M | |
| Pretax Income | $706.0K | $874.0K | $-24M | $-20M | $-13M | |
| Net Income | $706.0K | $874.0K | $-24M | $-20M | $-13M | |
| EPS (Basic) | $0.02 | $0.02 | $-0.85 | $-0.84 | $-0.58 | |
| EPS (Diluted) | $0.02 | $0.02 | $-0.85 | $-0.84 | $-0.58 | |
| Shares (Basic) | 29,204,376 | 29,068,076 | · | 23,530,877 | · | |
| Shares (Diluted) | 29,344,664 | 30,300,004 | · | 23,530,877 | · | |
| EBITDA | $-4M | $-10M | · | · | · |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $586.0K | $368.0K | $6M | · | $738.0K | |
| Receivables | $5M | $5M | · | · | · | |
| Inventory | $718.0K | $477.0K | $571.0K | · | $5M | |
| Prepaid Expense | $463.0K | $675.0K | $920.0K | · | $857.0K | |
| Current Assets | $6M | $6M | $12M | · | $21M | |
| PP&E (Net) | $53M | $55M | $56M | · | $62M | |
| PP&E (Gross) | $94M | $94M | $94M | · | $94M | |
| Accum. Depreciation | $41M | $40M | $39M | · | $33M | |
| Goodwill | $7M | $7M | $7M | · | $7M | |
| Intangibles | $6M | $7M | $8M | · | $9M | |
| Other Non-current Assets | $238.0K | $241.0K | $247.0K | · | $270.0K | |
| Total Assets | $96M | $99M | $107M | · | $133M | |
| Accounts Payable | $15M | $25M | $26M | · | $23M | |
| Accrued Liabilities | · | $31M | $33M | · | $20M | |
| Current Liabilities | $60M | $71M | $81M | · | $54M | |
| Capital Leases | $27M | $27M | $27M | · | $27M | |
| Deferred Tax | $12.0K | $12.0K | $12.0K | · | $9.0K | |
| Other Non-current Liabilities | $259.0K | $263.0K | $266.0K | · | $280.0K | |
| Total Liabilities | $132M | $135M | $145M | · | $124M | |
| Common Stock | $3.0K | $3.0K | $3.0K | · | $2.0K | |
| Paid-in Capital | $954M | $955M | $953M | · | $909M | |
| Retained Earnings | $-990M | $-991M | $-991M | · | $-900M | |
| AOCI | · | · | · | · | $-5.0K | |
| Stockholders' Equity | $-36M | $-35M | $-38M | · | $9M | |
| Liabilities + Equity | $96M | $99M | $107M | · | $133M | |
| Shares Outstanding | 29,283,614 | 29,179,751 | 28,837,787 | · | 22,546,671 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| D&A | $2M | $2M | $2M | $2M | $2M | |
| Stock-based Comp | $844.0K | $1M | · | $3M | · | |
| Amort. of Intangibles | $354.0K | $368.0K | · | $368.0K | $376.0K | |
| Operating Cash Flow | $-1M | $1M | $-5M | $-3M | $2M | |
| CapEx | · | · | · | · | $91.0K | |
| Investing Cash Flow | · | · | · | · | $-2M | |
| Stock Issued | · | · | $0 | $2M | · | |
| Financing Cash Flow | $1M | $-7M | $11M | $2M | $643.0K | |
| Net Change in Cash | $-83.0K | $-6M | $6M | $-673.0K | $646.0K |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Operating Margin | -78.0% | -263.5% | · | · | · | |
| Net Margin | 13.0% | 22.7% | · | · | · | |
| Pretax Margin | 13.0% | 22.7% | · | · | · | |
| EBITDA Margin | -78.0% | -263.5% | · | · | · | |
| ROA | 0.65% | 0.77% | · | · | · | |
| ROE | -2.3% | -4.3% | · | · | · |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Current Ratio | 0.1 | 0.1 | · | · | · | |
| Quick Ratio | 0.1 | 0.1 | · | · | · |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | · | · | · | |
| Inventory Turnover | 0.9 | 0.4 | · | · | · | |
| Receivables Turnover | 2.3 | 1.6 | · | · | · |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Book Value / Share | $-1.21 | $-1.21 | · | · | · | |
| Revenue / Share | $0.19 | $0.13 | · | · | · | |
| Cash Flow / Share | · | $0.05 | · | · | · | |
| Cash / Share | $0.02 | $0.01 | · | · | · | |
| EPS (TTM) | $-1.69 | $-2.73 | · | · | · |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Revenue TTM | $19M | $19M | · | · | · | |
| Net Income TTM | $-46M | $-71M | · | · | · | |
| Market Cap | $18M | $39M | · | · | · | |
| P/E | -0.4 | -0.5 | · | · | · | |
| P/S | 0.9 | 2.0 | · | · | · | |
| P/B | -0.5 | -1.1 | · | · | · | |
| P / Cash Flow | · | 26.8 | · | · | · | |
| Earnings Yield | -282.6% | -205.3% | · | · | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $27M | $54M |
| Net Income | $-92M | $-58M |
| Diluted EPS | $-3.59 | $-2.64 |
No data for this statement
Not enough fundamentals data to build this statement yet.
No data for this statement
Not enough fundamentals data to build this statement yet.
Institutional owners (13F) 37 filers · $3.2M total · As of Sept. 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
37
Value held
$3.2M
New positions
5
Exited positions
4
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 5 (-5 vs prior Q) | 4 (-2 vs prior Q) | 9 (+5 vs prior Q) | 4 (-1 vs prior Q) | +47K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| C V STARR & CO INC | $1,581,623 | 764,069 | 50.16% | Shares |
| VANGUARD GROUP INC | $751,082 | 676,650 | 23.82% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $371,421 | 621,105 | 11.78% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $99,957 | 167,150 | 3.17% | Shares |
| CITADEL ADVISORS LLC | $59,224 | 99,054 | 1.88% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $47,765 | 79,874 | 1.51% | Shares |
| BlackRock, Inc. | $45,655 | 76,359 | 1.45% | Shares |
| HB Wealth Management, LLC | $43,085 | 31,915 | 1.37% | Shares |
| STATE STREET CORP | $34,577 | 57,830 | 1.10% | Shares |
| NORTHERN TRUST CORP | $26,405 | 44,163 | 0.84% | Shares |
| Biltmore Family Office, LLC | $20,927 | 35,000 | 0.66% | Shares |
| KEYNOTE FINANCIAL SERVICES LLC | $17,889 | 29,920 | 0.57% | Shares |
| JANE STREET GROUP, LLC | $17,167 | 28,713 | 0.54% | Shares |
| ROYAL BANK OF CANADA | $11,000 | 18,000 | 0.35% | Shares |
| IPG Investment Advisors LLC | $10,265 | 17,169 | 0.33% | Shares |
| Tower Research Capital LLC (TRC) | $3,056 | 5,111 | 0.10% | Shares |
| SBI Securities Co., Ltd. | $2,541 | 1,882 | 0.08% | Shares |
| GROUP ONE TRADING LLC | $2,149 | 3,595 | 0.07% | Shares |
| WELLS FARGO & COMPANY/MN | $1,495 | 2,500 | 0.05% | Shares |
| Vanguard Global Advisers, LLC | $1,384 | 2,315 | 0.04% | Shares |
| SIMPLEX TRADING, LLC | $1,308 | 2,188 | 0.04% | Shares |
| UBS Group AG | $1,005 | 1,680 | 0.03% | Shares |
| CoreCap Advisors, LLC | $675 | 500 | 0.02% | Shares |
| CALDWELL SUTTER CAPITAL, INC. | $598 | 1,000 | 0.02% | Shares |
| HighMark Wealth Management LLC | $263 | 441 | 0.01% | Shares |
| Global Retirement Partners, LLC | $179 | 300 | 0.01% | Shares |
| VALLEY NATIONAL ADVISERS INC | $135 | 100 | 0.00% | Shares |
| Financial Perspectives, Inc | $102 | 171 | 0.00% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $59 | 99 | 0.00% | Shares |
| JONES FINANCIAL COMPANIES LLLP | $51 | 82 | 0.00% | Shares |
| HRT FINANCIAL LP | $33 | 56,591 | 0.00% | Shares |
| MORGAN STANLEY | $13 | 21 | 0.00% | Shares |
| Virtu Financial LLC | $11 | 18,697 | 0.00% | Shares |
| United Financial Planning Group LLC | $11 | 19 | 0.00% | Shares |
| JPMORGAN CHASE & CO | $10 | 16 | 0.00% | Shares |
| HARBOUR INVESTMENTS, INC. | $9 | 15 | 0.00% | Shares |
| DANSKE BANK A/S | $1 | 1 | 0.00% | Shares |
Activists & 5%+ owners 5 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| DANIELE BARACH, PHILIP & DANIELE BARACH FAMILY TRUST, PHILIP A. BARACH | Sept. 28, 2026 | 29.00% | Amendment | Board campaign | SEC |
| PHILP & DANIELE BARACH FAMILY TRUST, PHILIP A. BARACH, DANIELE BARACH | April 3, 2026 | 9.56% | Initial filing | Passive investment | SEC |
| Dragasac Limited, Resorts World Inc Pte. Ltd., Genting Berhad, Lim Kok Thay ×2 filings | July 28, 2025 | 41.00% | Amendment | · | SEC |
| Dragasac Limited, Resorts World Inc Pte. Ltd., Genting Berhad, Lim Kok Thay ×4 filings | March 15, 2024 | · | Initial filing | · | SEC |
| Robert J. Hariri, M.D., Ph.D. | July 26, 2021 | · | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 27 insiders · 10 officers · 12 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Robert J Hariri | Chief Executive Officer | Oct. 5, 2023 P | 28,570,434 | 0 | 0 | $0 |
| David C Beers | Chief Financial Officer | April 13, 2023 F | 287,405 | 0 | 0 | $0 |
| Andrew L Pecora | President | Sept. 15, 2021 A | · | 0 | 0 | $0 |
| Bradley Glover | Executive Vice President, Chief Operating Officer | April 13, 2023 F | 351,192 | 0 | 0 | $0 |
| Adrian Kilcoyne | Chief Medical Officer | July 14, 2023 A | 1,175,000 | 0 | 0 | $0 |
| Kyle Fletcher | Executive Vice President, General Counsel and Chief Compliance Officer | April 13, 2023 F | 256,799 | 0 | 0 | $0 |
| Stephen Brigido | Pres, Functional Regeneration | April 13, 2023 F | 230,126 | 0 | 0 | $0 |
| John R Haines | Senior EVP, Chief Administrative Officer | April 13, 2023 F | 459,847 | 0 | 0 | $0 |
| Anne Jones | Chief Business Officer | Nov. 16, 2022 F | 49,154 | 0 | 0 | $0 |
| Keary Dunn | General Counsel & Executive Vice President | April 13, 2022 A | 16,405 | 0 | 0 | $0 |
| Philip Alan Barach | Director | Sept. 23, 2026 J | · | 0 | 0 | $0 |
| Geoffrey Ling M.D. | Director | Aug. 31, 2023 A | · | 0 | 0 | $0 |
| Diane L. Parks | Director | June 14, 2023 A | 236,066 | 0 | 0 | $0 |
| Andrew C. Von Eschenbach | Director | June 14, 2023 A | 336,066 | 0 | 0 | $0 |
| Peter Diamandis | Director | June 14, 2023 A | 1,307,066 | 0 | 0 | $0 |
| Lim Kok Thay | Director | June 14, 2023 F | 225,222 | 0 | 0 | $0 |
| Robin L Smith | Director | June 14, 2023 A | 236,066 | 0 | 0 | $0 |
| Marc Mazur | Director | June 14, 2023 A | 236,066 | 0 | 0 | $0 |
| Dean C Kehler | Director | June 14, 2023 A | 236,066 | 0 | 0 | $0 |
| SCULLEY JOHN | Director | June 14, 2023 A | 1,004,660 | 0 | 0 | $0 |
| Jay R Bloom | Director | Sept. 9, 2021 A | 100,000 | 0 | 0 | $0 |
| DANIELE BARACH | 10% owner | Sept. 23, 2026 J | · | 0 | 0 | $0 |
| PHILP & DANIELE BARACH FAMILY TRUST | 10% owner | Sept. 23, 2026 J | · | 0 | 0 | $0 |
| Sorrento Therapeutics, Inc. | 10% owner | Oct. 5, 2023 S | 5,050,427 | 0 | 0 | $0 |
| Genting Berhad | 10% owner | June 20, 2023 P | · | 0 | 0 | $0 |
| GX Sponsor LLC | 10% owner | July 16, 2021 J | 100,000 | 0 | 0 | $0 |
| Beloo Mirakhur | · | Sept. 13, 2021 A | · | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 2 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
CELU Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 7 analysts
BUY
2 28.6%
Strong Buy
4 57.1%
Buy
1 14.3%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| CELU | · | -0.3 | -51.0% | · | · | · |
| LITS | $30M | -0.4 | 33.8% | · | -115.3% | · |
| CRVO | $73M | · | -58.9% | -673.1% | -104.4% | · |
| IRLA | · | · | · | · | · | · |
| MGX | $61M | -0.7 | -51.8% | -348.5% | -49.6% | · |
| RNAZ | · | -0.1 | · | · | · | · |
| ALGS | $58M | -3.8 | -39.5% | -1106.7% | -31.1% | · |
| ABVC | $53M | -5.5 | 234.3% | · | -128.2% | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Oct 20, 2026